Wegovy pill and Foundayo both set weekly prescription records

Both oral GLP-1 pills hit their highest weekly prescription totals yet in the period reported Sept. 11, 2026. Novo Nordisk's Wegovy pill reached about 183,000 total prescriptions, up from roughly 181,000 the week before, while Eli Lilly's Foundayo climbed nearly 8% to about 47,500, according to IQVIA data cited by Citi ^[1].

Foundayo remains roughly 135,000 weekly prescriptions behind the Wegovy pill ^[1]. The two are different medicines: the Wegovy pill is oral semaglutide, the same molecule as Novo's injectable Wegovy, and Foundayo is orforglipron ^[1]. The share gap between the two oral drugs has been narrowing slowly without closing, and Foundayo has not caught up ^[1].

Citi analysts cautioned that IQVIA may still be missing some Foundayo prescriptions filled through telehealth channels, so its actual total could be higher than the reported figure ^[1]. Earlier weekly notes flagged the same uncertainty, including whether some growth reflected better data capture rather than more patients ^[1].

Looking at the broader market, total GLP-1 prescriptions across obesity and diabetes uses rose 5.4% over the last four weeks, compared with a 6.8% decline in the same period a year earlier, a 12-percentage-point swing Citi attributed to oral GLP-1s broadening access and bringing in new patients ^[1]. Lilly's tirzepatide, sold as Zepbound and Mounjaro, held about 57% of the total GLP-1 market, up from about 49.5% a year earlier, while Novo's semaglutide stayed roughly flat at 37% ^[1].

Foundayo crossed 40,000 weekly scripts for the first time in the Aug. 28 update, at 40,862, after a small dip the week before ^[1]. At that point the Wegovy pill, then in its 33rd week on the market, had about 175,000 prescriptions ^[1]. In a note released Aug. 28 based on the prior week's data, Jefferies put Foundayo's share of new prescriptions, which exclude refills, at 21.5% of the oral obesity market ^[1]. The Wegovy pill has hovered between 33% and 35% of all Wegovy prescriptions in recent weeks ^[1].

Why it matters for patients

Patients now have two oral GLP-1 options rather than only injections. Lilly is betting that Foundayo's freedom from strict fasting and water requirements can give it an edge over the Wegovy pill ^[1].

The rising prescription totals suggest more people are getting these medicines filled. The Medicare GLP-1 Bridge program went live July 1, offering coverage for certain weight-loss medicines, including Foundayo, at a $50 monthly copayment ^[1]. Coverage has also been uneven: CVS was the last of the three major pharmacy benefit managers to cover Foundayo, starting June 1, while Wegovy had full coverage from its first week on the market, according to Jefferies ^[1].

Weekly tracker updates describe prescription counts and market share, not how well either drug works for any individual. No head-to-head comparison of the two oral drugs appears in these updates, so which one performs better in patients has not been reported here.

What happens next

The tracker is updated weekly using IQVIA data cited by Citi and Jefferies, so new prescription totals are expected each week ^[1]. Lilly's second-quarter results, reported Aug. 5, showed $98 million in total Foundayo sales, including $67 million in the U.S. ^[1]. The date of Lilly's next quarterly report has not been disclosed in these updates ^[1].